Zelluna Immunotherapy announces investment from Takeda Ventures, Inc.
Zelluna Immunotherapy, a company focused on allogenic T-cell Receptor Natural Killer (TCR-NK) cells to treat…
August 25, 2022 - 2 minutes
Zelluna Immunotherapy, a company focused on allogenic T-cell Receptor Natural Killer (TCR-NK) cells to treat…